Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma clinical trial (NCT05645107). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential benefits and risks of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma clinical trial (NCT05645107). Contact the study team or your healthcare provider for specific answers.

Question 3

How often will I need to visit the clinic if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma clinical trial (NCT05645107). Contact the study team or your healthcare provider for specific answers.

Question 4

What will the treatment process look like, and how will I receive XEMBIFY®?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma clinical trial (NCT05645107). Contact the study team or your healthcare provider for specific answers.

Question 5

How does this trial compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma clinical trial (NCT05645107). Contact the study team or your healthcare provider for specific answers.

Question 6

What should I do if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma clinical trial (NCT05645107). Contact the study team or your healthcare provider for specific answers.

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

What this study is about

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

What this study is about